Study of the Vascular Effects of Serelaxin

NCT01979614 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronary Artery Disease

Interventions

DRUG: Serelaxin
OTHER: Placebo

Sponsor

Novartis Pharmaceuticals